Anti-inflammatory activity of an extract of Petasites hybridus in allergic rhinitis

• Published in: International immunopharmacology 2002-06, Vol.2 (7), p.997-1006
• Main Authors: Thomet, Olivier A.R., Schapowal, Andreas, Heinisch, Isabelle V.W.M., Wiesmann, Ulrich N., Simon, Hans-Uwe
• Format: Article
• Language: English
• Subjects: Adult; Allergic rhinitis; Anti-Inflammatory Agents, Non-Steroidal - pharmacology; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Antihistamines; Biological and medical sciences; Eosinophil cationic protein; Female; General pharmacology; Humans; Leukotriene receptor antagonists; Lymphocyte Subsets - cytology; Lymphocyte Subsets - drug effects; Lymphocyte Subsets - immunology; Male; Medical sciences; Petasites; Petasites hybridus; Pharmacognosy. Homeopathy. Health food; Pharmacology. Drug treatments; Phytotherapy - methods; Plant Extracts - pharmacology; Plant Extracts - therapeutic use; Quality of Life - psychology; Rhinitis, Allergic, Perennial - drug therapy; Rhinitis, Allergic, Perennial - immunology; Rhinitis, Allergic, Perennial - physiopathology; Rhinitis, Allergic, Perennial - psychology; Rhinomanometry; Statistics, Nonparametric
• ISSN: 1567-5769; 1878-1705
• DOI: 10.1016/S1567-5769(02)00046-2

Previous studies have suggested that histamine and leukotrienes (LTs) play an important pathobiological role in IgE-mediated allergic diseases. In vitro studies suggested that an extract of Petasites hybridus (Ze339) blocks LT synthesis in monocytes and granulocytes. Petasins are considered to be the pharmacologically active fraction within Ze339. Patients suffering from allergic rhinitis received three times a day two tablets of Ze339 standardized to 8 mg petasins within a time period of 1 week. After 5 days of treatment, Ze339 significantly improved primary end points, which were day- and nighttime nasal symptoms. Nasal resistance, which was measured by rhinomanometry, gradually decreased as a consequence of Ze339 treatment reaching normal levels after 5 days (rhinomanometry: from 403.5±62.0 to 844.8±38.8 ml). Levels of inflammatory mediators in nasal fluids and serum were measured 90 min after drug administration every day in the morning. After 5 days of treatment, a significant reduction of histamine (from 153.7±32.1 to 53.0±8.4 pg/ml) and LT levels (LTB 4: from 313.1±46.5 to 180.6±32.2 pg/ml; cysteinyl-LT: from 137.0±42.2 to 70.1±16.5 pg/ml) could be observed. Moreover, quality-of-life scores significantly improved. The drug had no effect on the distribution of lymphocyte subpopulations in the blood as well as on the capacity of blood leukocytes to generate cytokines and lipid mediators. These results suggest that Ze339 is effective in treating allergic rhinitis patients by decreasing levels of nasal inflammatory mediators.